RU2010119292A - Способный к интерференции дуплекс рнк, имеющий "тупые" концы и 3'-модификации - Google Patents
Способный к интерференции дуплекс рнк, имеющий "тупые" концы и 3'-модификации Download PDFInfo
- Publication number
- RU2010119292A RU2010119292A RU2010119292/10A RU2010119292A RU2010119292A RU 2010119292 A RU2010119292 A RU 2010119292A RU 2010119292/10 A RU2010119292/10 A RU 2010119292/10A RU 2010119292 A RU2010119292 A RU 2010119292A RU 2010119292 A RU2010119292 A RU 2010119292A
- Authority
- RU
- Russia
- Prior art keywords
- double
- stranded rna
- rna according
- chemical modification
- ribonucleotides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/311—Phosphotriesters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/332—Abasic residue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
- C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/30—Production chemically synthesised
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Apparatus For Disinfection Or Sterilisation (AREA)
Abstract
1. Двухцепочечная РНК по меньшей мере с одним «тупым» концом, где двухцепочечная РНК включает на 3'-конце по меньшей мере одной цепи химическую модификацию, где химической модификацией является сложный гироксипропилфосфодиэфир. ! 2. Двухцепочечная РНК по п.1, где двухцепочечная РНК включает химическую модификацию сложным гироксипропилфосфодиэфиром на 3'-конце обоих цепей. ! 3. Двухцепочечная РНК по п.1, где двухцепочечная РНК включает два тупых конца. ! 4. Двухцепочечная РНК по п.1, где двухцепочечная РНК включает два тупых конца и химическую модификацию сложным гироксипропилфосфодиэфиром на 3'-конце обоих цепей. ! 5. Двухцепочечная РНК по п.1, которая дополнительно включает по меньшей мере один модифицированный рибонуклеотид, содержащий 2'-алкоксильный заместитель. ! 6. Двухцепочечная РНК по п.5, где 2'-алкоксильный заместитель является 2'-O-(2 метоксиэтилом). ! 7. Двухцепочечная РНК по п.1, где двухцепочечная РНК включает участок из 19 смежных пар оснований рибонуклеотидов. ! 8. Двухцепочечная РНК по п.1, где двухцепочечная РНК имеет длину из 19 смежных пар оснований рибонуклеотидов. ! 9. Двухцепочечная РНК по п.1, где двухцепочечная РНК включает участок из 19 смежных пар оснований рибонуклеотидов и двухцепочечная РНК включает два тупых конца. ! 10. Двухцепочечная РНК по п.1, где двухцепочечная РНК включает участок из 19 смежных пар оснований рибонуклеотидов, двухцепочечная РНК включает два тупых конца и химическую модификацию сложным гироксипропилфосфодиэфиром на 3'-конце обоих цепей. ! 11. Двухцепочечная РНК по п.1, где двухцепочечная РНК имеет длину из 19 смежных пар оснований рибонуклеотидов, двухцепочечная РНК включает два тупых
Claims (15)
1. Двухцепочечная РНК по меньшей мере с одним «тупым» концом, где двухцепочечная РНК включает на 3'-конце по меньшей мере одной цепи химическую модификацию, где химической модификацией является сложный гироксипропилфосфодиэфир.
2. Двухцепочечная РНК по п.1, где двухцепочечная РНК включает химическую модификацию сложным гироксипропилфосфодиэфиром на 3'-конце обоих цепей.
3. Двухцепочечная РНК по п.1, где двухцепочечная РНК включает два тупых конца.
4. Двухцепочечная РНК по п.1, где двухцепочечная РНК включает два тупых конца и химическую модификацию сложным гироксипропилфосфодиэфиром на 3'-конце обоих цепей.
5. Двухцепочечная РНК по п.1, которая дополнительно включает по меньшей мере один модифицированный рибонуклеотид, содержащий 2'-алкоксильный заместитель.
6. Двухцепочечная РНК по п.5, где 2'-алкоксильный заместитель является 2'-O-(2 метоксиэтилом).
7. Двухцепочечная РНК по п.1, где двухцепочечная РНК включает участок из 19 смежных пар оснований рибонуклеотидов.
8. Двухцепочечная РНК по п.1, где двухцепочечная РНК имеет длину из 19 смежных пар оснований рибонуклеотидов.
9. Двухцепочечная РНК по п.1, где двухцепочечная РНК включает участок из 19 смежных пар оснований рибонуклеотидов и двухцепочечная РНК включает два тупых конца.
10. Двухцепочечная РНК по п.1, где двухцепочечная РНК включает участок из 19 смежных пар оснований рибонуклеотидов, двухцепочечная РНК включает два тупых конца и химическую модификацию сложным гироксипропилфосфодиэфиром на 3'-конце обоих цепей.
11. Двухцепочечная РНК по п.1, где двухцепочечная РНК имеет длину из 19 смежных пар оснований рибонуклеотидов, двухцепочечная РНК включает два тупых конца и химическую модификацию сложным гироксипропилфосфодиэфиром на 3'-конце обоих цепей.
12. Фармацевтическая композиция, содержащая двухцепочечную РНК по п.1.
13. Двухцепочечная РНК по п.1 для применения в качестве лекарственного средства для селективного ингибирования гена-мишени.
14. Двухцепочечная РНК по п.1 для применения для приготовления лекарственного средства для селективного ингибирования гена-мишени.
15. Двухцепочечная РНК по п.1 для применения для селективного ингибирования гена-мишени in vitro или у животных, кроме человека.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49851403P | 2003-08-28 | 2003-08-28 | |
| US60/498,514 | 2003-08-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2010119292A true RU2010119292A (ru) | 2011-12-10 |
Family
ID=34272687
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006109547/13A RU2399671C2 (ru) | 2003-08-28 | 2004-08-27 | Способный к интерференции дуплекс рнк, имеющий "тупые" концы и 3'-модификации |
| RU2010119292/10A RU2010119292A (ru) | 2003-08-28 | 2010-05-14 | Способный к интерференции дуплекс рнк, имеющий "тупые" концы и 3'-модификации |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006109547/13A RU2399671C2 (ru) | 2003-08-28 | 2004-08-27 | Способный к интерференции дуплекс рнк, имеющий "тупые" концы и 3'-модификации |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US20070203084A1 (ru) |
| EP (3) | EP2489737A1 (ru) |
| JP (2) | JP2007503803A (ru) |
| KR (3) | KR20060087531A (ru) |
| CN (2) | CN1845993B (ru) |
| AU (1) | AU2004269150C1 (ru) |
| BR (1) | BRPI0413146A (ru) |
| CA (1) | CA2536333C (ru) |
| CO (1) | CO5680494A2 (ru) |
| EC (1) | ECSP066388A (ru) |
| IL (1) | IL173565A (ru) |
| IS (1) | IS8358A (ru) |
| MA (1) | MA28029A1 (ru) |
| MX (1) | MXPA06002216A (ru) |
| NO (1) | NO20061345L (ru) |
| NZ (1) | NZ545360A (ru) |
| RU (2) | RU2399671C2 (ru) |
| SG (1) | SG152279A1 (ru) |
| TN (1) | TNSN06065A1 (ru) |
| WO (1) | WO2005021749A1 (ru) |
| ZA (1) | ZA200601003B (ru) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070203084A1 (en) | 2003-08-28 | 2007-08-30 | Jan Weiler | Interfering Rna Duplex Having Blunt-Ends And 3'-Modifications |
| GB0608838D0 (en) | 2006-05-04 | 2006-06-14 | Novartis Ag | Organic compounds |
| WO2008049078A1 (en) * | 2006-10-18 | 2008-04-24 | Nastech Pharmaceutical Company Inc. | Nicked or gapped nucleic acid molecules and uses thereof |
| JP4900943B2 (ja) * | 2006-12-25 | 2012-03-21 | 独立行政法人産業技術総合研究所 | ヌクレアーゼ耐性及びｒｎａ干渉効果に優れた修飾型二本鎖ｒｎａ |
| JP5558346B2 (ja) | 2007-07-05 | 2014-07-23 | ノバルティス アーゲー | ウイルス感染を処置するためのｄｓＲＮＡ |
| WO2009118300A1 (en) | 2008-03-25 | 2009-10-01 | Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Treating cancer by down-regulating frizzled-4 and/or frizzled-1 |
| WO2010100247A1 (en) | 2009-03-06 | 2010-09-10 | Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research | Novel therapy for anxiety |
| EP2241323A1 (en) | 2009-04-14 | 2010-10-20 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Tenascin-W and brain cancers |
| EP2292266A1 (en) | 2009-08-27 | 2011-03-09 | Novartis Forschungsstiftung, Zweigniederlassung | Treating cancer by modulating copine III |
| US20120244170A1 (en) | 2009-09-22 | 2012-09-27 | Rafal Ciosk | Treating cancer by modulating mex-3 |
| WO2011045352A2 (en) | 2009-10-15 | 2011-04-21 | Novartis Forschungsstiftung | Spleen tyrosine kinase and brain cancers |
| TWI611021B (zh) | 2009-12-09 | 2018-01-11 | 日東電工股份有限公司 | Ｈｓｐ４７表現之調節 |
| BR112012014760A2 (pt) | 2009-12-18 | 2016-06-14 | Novartis Ag | "composições orgânicas para tratar doenças relacionadas a hsf1, bem como seu uso" |
| BR112012015755B1 (pt) | 2009-12-23 | 2021-06-22 | Novartis Ag | Lipídeo furtivo, e composição |
| WO2011098449A1 (en) | 2010-02-10 | 2011-08-18 | Novartis Ag | Methods and compounds for muscle growth |
| WO2011107586A1 (en) | 2010-03-05 | 2011-09-09 | Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research, | Smoc1, tenascin-c and brain cancers |
| EP2561076A1 (en) | 2010-04-19 | 2013-02-27 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Modulating xrn1 |
| WO2011133876A2 (en) * | 2010-04-22 | 2011-10-27 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides comprising acyclic and abasic nucleosides and analogs |
| EP2561077B1 (en) | 2010-04-23 | 2016-04-13 | Arrowhead Research Corporation | ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES |
| US20130089538A1 (en) | 2010-06-10 | 2013-04-11 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute forBiomedical Researh | Treating cancer by modulating mammalian sterile 20-like kinase 3 |
| US9181553B2 (en) | 2011-06-06 | 2015-11-10 | Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Method of treatment of breast cancers over-expressing the SHP2 signature genes |
| RU2665549C1 (ru) * | 2011-07-18 | 2018-08-30 | Девген Нв | Подавление экспрессии генов у насекомых-вредителей |
| EP3098314B1 (en) | 2011-09-02 | 2019-03-13 | Arrowhead Pharmaceuticals, Inc. | Organic compositions to treat hsf1-related diseases |
| EP2776838A1 (en) | 2011-11-08 | 2014-09-17 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Early diagnostic of neurodegenerative diseases |
| WO2013068431A1 (en) | 2011-11-08 | 2013-05-16 | Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research | New treatment for neurodegenerative diseases |
| RU2014124184A (ru) | 2011-11-15 | 2015-12-27 | Новартис Аг | Комбинация ингибитора фосфоинозитид-3-киназы и модулятора пути янус-киназы 2 - проводника сигнала и активатора транскрипции 5 |
| US20140363448A1 (en) | 2012-01-02 | 2014-12-11 | Novartis Ag | Cdcp1 and breast cancer |
| WO2013105022A2 (en) | 2012-01-09 | 2013-07-18 | Novartis Ag | Organic compositions to treat beta-catenin-related diseases |
| EP2831112A1 (en) | 2012-03-29 | 2015-02-04 | Friedrich Miescher Institute for Biomedical Research | Inhibition of interleukin- 8 and/or its receptor cxcrl in the treatment her2/her3 -overexpressing breast cancer |
| EP3272868A1 (en) | 2012-05-02 | 2018-01-24 | Arrowhead Pharmaceuticals, Inc. | Organic compositions to treat kras-related diseases |
| KR101567576B1 (ko) * | 2012-05-22 | 2015-11-10 | 올릭스 주식회사 | 세포 내 관통능을 가지고 ｒｎａ 간섭을 유도하는 핵산 분자 및 그 용도 |
| WO2014001482A1 (en) | 2012-06-29 | 2014-01-03 | Novartis Forschungsstiftung, Zweigniererlassung, Friedrich Miescher Institute For Biomedical Research | Treating diseases by modulating a specific isoform of mkl1 |
| US20150184154A1 (en) | 2012-07-05 | 2015-07-02 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear | New treatment for neurodegenerative diseases |
| WO2014006115A1 (en) | 2012-07-06 | 2014-01-09 | Novartis Ag | Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the il-8/cxcr interaction |
| EP2961843A2 (en) | 2013-02-28 | 2016-01-06 | Arrowhead Research Corporation | Organic compositions to treat epas1-related diseases |
| KR102144777B1 (ko) * | 2013-06-19 | 2020-08-18 | 제이더블유중외제약 주식회사 | 결정형 메로페넴 삼수화물의 제조방법 |
| WO2015019286A1 (en) | 2013-08-07 | 2015-02-12 | Friedrich Miescher Institute For Biomedical Research | New screening method for the treatment friedreich's ataxia |
| WO2015051135A2 (en) | 2013-10-04 | 2015-04-09 | Novartis Ag | Organic compositions to treat hepcidin-related diseases |
| EP3052627B1 (en) | 2013-10-04 | 2018-08-22 | Novartis AG | Novel formats for organic compounds for use in rna interference |
| WO2015051044A2 (en) | 2013-10-04 | 2015-04-09 | Novartis Ag | Novel formats for organic compounds for use in rna interference |
| CA2925129C (en) | 2013-10-04 | 2023-04-04 | Novartis Ag | 3' end caps for rnai agents for use in rna interference |
| CN105792832B (zh) | 2013-10-04 | 2021-03-23 | 诺华股份有限公司 | 用于***病毒的有机化合物 |
| KR101696704B1 (ko) * | 2013-12-17 | 2017-01-16 | 주식회사 인코드젠 | 오프-타겟을 막기 위해 변형된 rna 간섭 유도 핵산 및 그 용도 |
| EP3154579A1 (en) | 2014-06-13 | 2017-04-19 | Friedrich Miescher Institute for Biomedical Research | New treatment against influenza virus |
| EP3164129A1 (en) | 2014-07-01 | 2017-05-10 | Friedrich Miescher Institute for Biomedical Research | Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma |
| WO2016010840A1 (en) | 2014-07-16 | 2016-01-21 | Novartis Ag | Method of encapsulating a nucleic acid in a lipid nanoparticle host |
| EP3736334A1 (en) | 2014-07-16 | 2020-11-11 | Arrowhead Pharmaceuticals, Inc. | Rnai compositions to treat apoc3-related diseases |
| EP3191592A1 (en) | 2014-09-11 | 2017-07-19 | Novartis AG | Inhibition of prmt5 to treat mtap-deficiency-related diseases |
| US20170298360A1 (en) | 2014-09-24 | 2017-10-19 | Friedrich Miescher Institute For Biomedical Research | Lats and breast cancer |
| US10479997B2 (en) | 2014-12-01 | 2019-11-19 | Novartis Ag | Compositions and methods for diagnosis and treatment of prostate cancer |
| US20180296537A1 (en) | 2015-06-05 | 2018-10-18 | Novartis Ag | Methods and compositions for diagnosing, treating, and monitoring treatment of shank3 deficiency associated disorders |
| US20180348224A1 (en) | 2015-10-28 | 2018-12-06 | Friedrich Miescher Institute For Biomedical Resear Ch | Tenascin-w and biliary tract cancers |
| JOP20200228A1 (ar) | 2015-12-21 | 2017-06-16 | Novartis Ag | تركيبات وطرق لخفض تعبير البروتين tau |
| US9721645B1 (en) | 2016-01-29 | 2017-08-01 | Taiwan Semiconductor Manufacturing Company, Ltd. | SRAM arrays and methods of manufacturing same |
| WO2018047148A1 (en) | 2016-09-12 | 2018-03-15 | Novartis Ag | Compounds for the inhibition of mirna |
| WO2018083606A1 (en) | 2016-11-01 | 2018-05-11 | Novartis Ag | Methods and compositions for enhancing gene editing |
| EP4085919A3 (en) | 2017-07-21 | 2023-02-08 | Novartis AG | Compositions and methods to treat cancer |
| US10597657B2 (en) | 2017-09-11 | 2020-03-24 | Arrowhead Pharmaceuticals, Inc. | RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3) |
| WO2019213276A1 (en) | 2018-05-02 | 2019-11-07 | Novartis Ag | Regulators of human pluripotent stem cells and uses thereof |
| WO2024134505A1 (en) | 2022-12-20 | 2024-06-27 | Novartis Ag | Nucleic acid ligation method |
| WO2024134502A1 (en) | 2022-12-20 | 2024-06-27 | Novartis Ag | Engineered double-strand rna ligases and uses thereof |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0942000T3 (da) | 1989-10-24 | 2004-11-01 | Isis Pharmaceuticals Inc | 2'-modificerede oligonukleotider |
| US5670633A (en) | 1990-01-11 | 1997-09-23 | Isis Pharmaceuticals, Inc. | Sugar modified oligonucleotides that detect and modulate gene expression |
| US6399754B1 (en) | 1991-12-24 | 2002-06-04 | Isis Pharmaceuticals, Inc. | Sugar modified oligonucleotides |
| US6005087A (en) | 1995-06-06 | 1999-12-21 | Isis Pharmaceuticals, Inc. | 2'-modified oligonucleotides |
| IL104461A (en) | 1992-01-22 | 2001-05-20 | Hoechst Ag | Analogs of oligonucleotide, their preparation and pharmaceutical preparations containing them |
| US6033909A (en) | 1992-01-22 | 2000-03-07 | Hoechst Aktiengesellschaft | Oligonucleotide analogs, their preparation and use |
| US5981501A (en) | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
| IL122290A0 (en) | 1995-06-07 | 1998-04-05 | Inex Pharmaceuticals Corp | Lipid-nucleic acid complex its preparation and use |
| US5998203A (en) * | 1996-04-16 | 1999-12-07 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures |
| US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| CA2289702C (en) | 1997-05-14 | 2008-02-19 | Inex Pharmaceuticals Corp. | High efficiency encapsulation of charged therapeutic agents in lipid vesicles |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| US6211349B1 (en) | 1998-12-30 | 2001-04-03 | Oligos Etc., Inc. | Protonated/acidified nucleic acids and methods of use |
| WO2000044914A1 (en) | 1999-01-28 | 2000-08-03 | Medical College Of Georgia Research Institute, Inc. | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| DE10160151A1 (de) | 2001-01-09 | 2003-06-26 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens |
| US8202979B2 (en) | 2002-02-20 | 2012-06-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid |
| US20070026394A1 (en) | 2000-02-11 | 2007-02-01 | Lawrence Blatt | Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies |
| WO2005019453A2 (en) | 2001-05-18 | 2005-03-03 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) |
| WO2003070918A2 (en) * | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Incorporated | Rna interference by modified short interfering nucleic acid |
| US20050233329A1 (en) | 2002-02-20 | 2005-10-20 | Sirna Therapeutics, Inc. | Inhibition of gene expression using duplex forming oligonucleotides |
| IL151928A0 (en) | 2000-03-30 | 2003-04-10 | Whitehead Biomedical Inst | Rna sequence-specific mediators of rna interference |
| US20030190635A1 (en) | 2002-02-20 | 2003-10-09 | Mcswiggen James A. | RNA interference mediated treatment of Alzheimer's disease using short interfering RNA |
| RU2322500C2 (ru) | 2000-12-01 | 2008-04-20 | Макс-Планк-Гезелльшафт Цур Фердерунг Дер Виссеншафтен Е.Ф. | Малые молекулы рнк, опосредующие интерференцию рнк |
| EP1229134A3 (en) | 2001-01-31 | 2004-01-28 | Nucleonics, Inc | Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell |
| US20030175950A1 (en) | 2001-05-29 | 2003-09-18 | Mcswiggen James A. | RNA interference mediated inhibition of HIV gene expression using short interfering RNA |
| US20040019001A1 (en) | 2002-02-20 | 2004-01-29 | Mcswiggen James A. | RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA |
| US20070032441A1 (en) | 2001-05-18 | 2007-02-08 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina) |
| CA2448320A1 (en) * | 2001-05-29 | 2002-12-05 | Sirna Therapeutics, Inc. | Ribozyme based treatment of female reproductive diseases |
| US20090247606A1 (en) | 2001-08-28 | 2009-10-01 | Sirna Therapeutics, Inc. | RNA Interference Mediated Inhibition of Adenosine A1 Receptor (ADORA1) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
| US8258288B2 (en) | 2002-02-20 | 2012-09-04 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of respiratory syncytial virus (RSV) expression using short interfering nucleic acid (siNA) |
| AU2003207708A1 (en) | 2002-02-20 | 2003-09-09 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of map kinase genes |
| ES2280826T5 (es) * | 2002-08-05 | 2017-08-03 | Silence Therapeutics Gmbh | Nuevas formas adicionales de moléculas de ARN de interferencia |
| ES2389024T3 (es) * | 2002-08-05 | 2012-10-22 | Silence Therapeutics Aktiengesellschaft | Moléculas de RNA interferentes de extremos romos |
| EP1608733B1 (en) * | 2003-04-02 | 2011-12-07 | Dharmacon, Inc. | Modified polynucleotides for use in rna interference |
| WO2004092383A2 (en) * | 2003-04-15 | 2004-10-28 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF SEVERE ACUTE RESPIRATORY SYNDROME (SARS) VIRUS GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| WO2004094595A2 (en) | 2003-04-17 | 2004-11-04 | Alnylam Pharmaceuticals Inc. | MODIFIED iRNA AGENTS |
| WO2005009346A2 (en) | 2003-06-24 | 2005-02-03 | Mirus Corporation | Inhibition of gene function by delivery of polynucleotide-based gene expression inhibitors to mammalian cells in vivo |
| US20070203084A1 (en) | 2003-08-28 | 2007-08-30 | Jan Weiler | Interfering Rna Duplex Having Blunt-Ends And 3'-Modifications |
| US7928217B2 (en) | 2004-05-27 | 2011-04-19 | Alnylam Pharmaceuticals, Inc. | Nuclease resistant double-stranded ribonucleic acid |
| GB0608838D0 (en) | 2006-05-04 | 2006-06-14 | Novartis Ag | Organic compounds |
-
2004
- 2004-08-27 US US10/569,927 patent/US20070203084A1/en not_active Abandoned
- 2004-08-27 MX MXPA06002216A patent/MXPA06002216A/es active IP Right Grant
- 2004-08-27 RU RU2006109547/13A patent/RU2399671C2/ru not_active IP Right Cessation
- 2004-08-27 SG SG200902906-7A patent/SG152279A1/en unknown
- 2004-08-27 EP EP12151831A patent/EP2489737A1/en not_active Withdrawn
- 2004-08-27 CN CN2004800249803A patent/CN1845993B/zh active Active
- 2004-08-27 EP EP04764573A patent/EP1660657A1/en not_active Ceased
- 2004-08-27 KR KR1020067004048A patent/KR20060087531A/ko not_active Application Discontinuation
- 2004-08-27 KR KR1020087007645A patent/KR101059315B1/ko not_active IP Right Cessation
- 2004-08-27 WO PCT/EP2004/009599 patent/WO2005021749A1/en active Application Filing
- 2004-08-27 CA CA2536333A patent/CA2536333C/en active Active
- 2004-08-27 CN CN2010101678324A patent/CN101914533B/zh not_active Expired - Fee Related
- 2004-08-27 EP EP10184568A patent/EP2338995A3/en not_active Withdrawn
- 2004-08-27 JP JP2006524342A patent/JP2007503803A/ja active Pending
- 2004-08-27 NZ NZ545360A patent/NZ545360A/en not_active IP Right Cessation
- 2004-08-27 KR KR1020117000474A patent/KR20110007263A/ko not_active Application Discontinuation
- 2004-08-27 AU AU2004269150A patent/AU2004269150C1/en active Active
- 2004-08-27 BR BRPI0413146-0A patent/BRPI0413146A/pt not_active IP Right Cessation
-
2006
- 2006-02-03 ZA ZA200601003A patent/ZA200601003B/en unknown
- 2006-02-06 IL IL173565A patent/IL173565A/en active IP Right Grant
- 2006-02-22 EC EC2006006388A patent/ECSP066388A/es unknown
- 2006-02-27 TN TNP2006000065A patent/TNSN06065A1/en unknown
- 2006-03-08 MA MA28861A patent/MA28029A1/fr unknown
- 2006-03-17 IS IS8358A patent/IS8358A/is unknown
- 2006-03-21 CO CO06027688A patent/CO5680494A2/es not_active Application Discontinuation
- 2006-03-24 NO NO20061345A patent/NO20061345L/no not_active Application Discontinuation
-
2008
- 2008-12-18 US US12/338,601 patent/US8097716B2/en active Active
-
2010
- 2010-05-14 RU RU2010119292/10A patent/RU2010119292A/ru not_active Application Discontinuation
- 2010-08-26 JP JP2010189117A patent/JP2011160796A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2010119292A (ru) | Способный к интерференции дуплекс рнк, имеющий "тупые" концы и 3'-модификации | |
| RU2010120715A (ru) | Модифицированная липидом двухцепочечная рнк, обладающая сильным эффектом рнк-интерференции | |
| CY1110915T1 (el) | Ολιγονουκλεοτιδια αναστολεις και χρηση αυτων για ειδικη καταστολη ενος γονιδιου κωδικοποιει υποδοχεα ανδρογονων | |
| IL166546A (en) | Double-stranded ribonucleic acid, preparations containing it, is used in drug preparation and in vitro method to inhibit the expression of a target gene | |
| WO2007143315A3 (en) | Compounds and methods for modulating expression of pcsk9 | |
| DE50214266D1 (de) | Verfahren zur hemmung der expression eines zielgens und medikament zur therapie einer tumorerkrankung | |
| WO2008109450A4 (en) | Nucleic acid compounds for inhibiting id-1 gene expression and uses thereof | |
| WO2003020949A3 (en) | Targeted nucleic acid constructs and uses related thereto | |
| WO2004035765A3 (en) | Double-stranded rna structures and constructs, and methods for generating and using the same | |
| CO6241169A2 (es) | Metodos para el tratamiento de hipercolesterolemia | |
| WO2007134161A3 (en) | Compositions and methods for inhibiting expression of the pcsk9 gene | |
| CA2520541A1 (en) | Antisense oligonucleotides (odn) against smad7 and uses thereof in medical field | |
| DK1175489T3 (da) | Oligonukleotider indeholdende en antisense-sekvens stabiliseret af en sekundær struktur og farmaceutiske præparater indeholdende disse oligonukleotider | |
| WO2008109362B1 (en) | Nucleic acid compounds for inhibiting vegf gene expression and uses thereof | |
| ATE334670T1 (de) | Verwendung von mek-inhibitoren zur herstellung eines arzneimittels gegen negativstrang-rna-viren infektionen | |
| DK1272501T3 (da) | Fremgangsmåde til fremstilling af phosphorthioattriestere | |
| WO2008109350A4 (en) | Nucleic acid compounds for inhibiting il6 gene expression and uses thereof | |
| WO2008109556B1 (en) | Nucleic acid compounds for inhibiting telomerase gene expression and uses thereof | |
| WO2008109474B1 (en) | Nucleic acid compounds for inhibiting fgf2 gene expression and uses thereof | |
| JP6830441B2 (ja) | 治療上のｕｎａオリゴマーおよびその使用 | |
| Flores et al. | Antimalarial antisense activity of hexitol nucleic acids | |
| WO2008109503B1 (en) | Nucleic acid compounds for inhibiting ms4a1 gene expression and uses thereof | |
| WO2008109493A4 (en) | NUCLEIC ACID COMPOUNDS DESIGNED TO INHIBIT EXPRESSION OF CD19 GENE AND USES THEREOF | |
| JP2004275169A5 (ru) | ||
| WO2008109505B1 (en) | Nucleic acid compounds for inhibiting cd22 gene expression and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20130325 |